Highest-materiality recent filing
Progyny shareholders approve elimination of supermajority voting requirements
Super majority amendments passed with >65M votes for, 357K against.
Progyny board approves $200M share repurchase program
Board authorized repurchase of up to $200M of common stock, funded from available cash balances.
Progyny Q1 rev $328.5M (+1.4%), adj EPS $0.50; guides FY rev $1.365-1.405B
Q1 revenue $328.5M (+1.4% YoY); ex-lost client revenue grew 12.2%. Net income $24.2M ($0.29 diluted) vs $15.1M.
Progyny settles derivative suit over director pay; caps annual comp at $288k per director
Derivative action challenged non-employee director compensation since 2020; settlement includes governance reforms.
Progyny Q4 revenue up 6.7% to $318.4M; guides FY2026 revenue $1.355B-$1.405B
Q4 revenue $318.4M (+6.7% YoY); FY2025 revenue $1.2887B (+10% YoY); gross margin expanded to 24.1%.
Progyny expects Q4 2025 revenue, net income, Adj. EBITDA slightly above prior guidance
CEO cites favorable Q4 member engagement vs. November guidance.
Progyny President Michael Sturmer to depart Dec 31, 2025; no successor named
President Michael Sturmer's employment ends Dec 31, 2025.
Progyny Q3 revenue $313.3M (+9.3% YoY), raises FY2025 guidance; board authorizes $200M buyback
Revenue $313.3M (+9.3% YoY), net income $13.9M ($0.15 EPS), adj. EBITDA $55.0M (17.5% margin).
Progyny Q2 revenue $332.9M (+9.5% YoY); raises FY2025 guidance on strong member engagement
Q2 revenue $332.9M, up 9.5% YoY; ex-large-client transition revenue grew 18%.
Progyny enters $200M credit facility; Q2 results expected slightly above guidance
Entered $200M revolving credit facility maturing July 1, 2030; undrawn at closing.
Progyny shareholders reject advisory vote on executive compensation at 2025 annual meeting
Director nominees Norman Payson, Debra Morris, Elizabeth Bierbower elected with majority votes.
Progyny Q1 revenue $324M (+16.5% YoY), raises FY2025 guidance above prior outlook
Q1 revenue $324.0M (+16.5% YoY); gross margin 23.4% vs 22.4% a year ago.
Director Dr. Fred E. Cohen to leave Progyny board after 2025 Annual Meeting
Dr. Cohen notified Progyny on April 9, 2025 of his decision not to stand for reelection at the 2025 Annual Meeting.
Q4 2024 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 EPS); Adj. EBITDA $47.5M (15.9% margin).
Progyny Q4 rev $298.4M (+10.6%); large client non-renewal pressures 2025 guide of 1-5% growth
Q4 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 diluted EPS) vs $13.5M ($0.13) prior year.
Progyny appoints Debra Morris to board effective Jan 16, 2025
Debra Morris appointed as Class III director, term expires at 2025 annual meeting.
Progyny expects Q4 2024 revenue, net income, Adjusted EBITDA slightly above prior guidance
Company updates guidance at JPM Healthcare Conference; Q4 results expected slightly above November ranges.
Progyny Q3 revenue up 2% to $286.6M, net income falls 34% to $10.4M; cuts FY2024 guidance
Revenue $286.6M (+2% YoY); net income $10.4M ($0.11 diluted EPS) vs $15.9M ($0.16) in Q3 2023.
Progyny loses client representing ~12-13% of revenue; termination effective Jan 1, 2025
Client with ~670k members exercised 90-day termination option; no disputes or service issues cited.
Progyny holds inaugural Investor Day; presentation furnished without new financial data
Hosted first-ever Investor Day on August 12, 2024; webcast replay available on website.
Progyny Q2 beats on adjusted EBITDA but cuts full-year guidance on lower revenue per member
Q2 revenue $304.1M (+8.8% YoY), record Adj. EBITDA $54.5M (+15% YoY), margin 17.9%.
Progyny stockholders re-elect directors, ratify EY, approve say-on-pay at 2024 annual meeting
Elected directors Anevski, Holstein, Park, Schlanger with 62M+ votes for each; broker non-votes 5,878,612.
Progyny board authorizes $100M share repurchase program
Board approved a new $100M share repurchase program on May 22, 2024.
Progyny Q1 revenue up 7.6% to $278M; cuts FY revenue guidance to $1.23-1.27B
Q1 revenue $278.1M (+7.6% YoY), net income $16.9M ($0.17 diluted EPS), adjusted EPS $0.39.
Progyny reports record FY23 revenue $1.09B (+38%); guides FY24 $1.285-$1.315B
FY23 revenue $1,088.6M (+38% YoY); net income $62.0M ($0.62 diluted EPS), adj. EBITDA $187.1M (+49%).
On April 9, 2025, Dr. Fred E. Cohen notified the Board of Directors of Progyny, Inc. (the “Company”) of his decision not to stand for reelection at the Company’s 2025 Annual Meeting of Stockholders.
On January 10, 2025, the board of directors (the “Board”) of Progyny, Inc. (the “Company”) appointed Debra Morris to serve as a Class III director of the Company, effective January 16, 2025.
Max materiality 0.85 · Median 0.70 · Most common event earnings